October12, 2020
NEWS RELEASE
Company:
Representative:

Contact:Telephone:

KYORIN Holdings, Inc.
Yutaka Ogihara
Representative Director, President(Securities Code: 4569, TSE 1st Sec.)
Yoshinori Tanifuji
Director, Corporate Planning(0)3-3525-4707

KYORIN assigns Intellectual Properties regarding KRP-203 to Priothera
KYORIN Holdings, Inc. today announced that its wholly owned subsidiary of KYORIN PharmaceuticalCo., Ltd. (Head office: Chiyoda-ku, Tokyo, President & CEO: Shigeru Ogihara, "Kyorin") has enteredinto an asset purchase agreement with Priothera Limited (Head office: Dublin, Ireland, CEO: FlorentGros, "Priothera") regarding the intellectual properties of KRP-203, a novel immunomodulator
developed by Kyorin.
Under the terms of the agreement, Kyorin will receive considerations including ordinary shares issued byPriothera, for the assignment of the KRP-203 assets such as intellectual rights and drug substance fordevelopment. In addition, Kyorin reserves the exclusive license to develop and commercialize KRP-203
in Japan and Korea.
KRP-203 is a novel sphingosine 1 phosphate receptor (S1P receptor) modulator having the action ofimmunomodulation by reducing egress of lymphocytes from lymph nodes.
Kyorin granted Novartis
rights to develop and commercialize KRP-203 as a treatment of patients with GvHD (graft-versus-hostdisease). Novartis terminated its development and returned the license to Kyorin in February 2018.
Priothera has now purchased KRP-203 and will develop it in acute myeloid leukemia (AML) patients
undergoing hematopoietic stem cell transplantation (HSCT). It is expected that KRP-203 would be amore effective and safer agent for AML patients than the existing immunomodulators.
Kyorin is pursuing contribution to health of people around the world by maximizing value of the novel
candidate compound discovered in house with rapid global development and by developing original new
drugs which meet medical needs.
The impact of the transaction on business performance for the fiscal year ending March 2021 is expected
to be negligible.

About Priothera Limited
Foundation:
2020
CEO:
Florent Gros
Overview:

Priothera is leading the way in developing orally applied sphingosine 1 phosphate
receptor modulators for haematological malignancies. S1P receptor modulators
have been suggested to largely reduce egress of T cell subsets from lymphatic
tissues allowing for dual inhibition of graft-versus-host-disease and enhancing
graft-versus-leukemia benefits in patients receiving allogenic stem cell transplant.
Headquartered in Dublin, Ireland, Priothera was founded in 2020 by Drs. Florent
Gros and Dhaval Patel. Joining the founding management team is the experienced
industry executive, Dr Simone Seiter.
Founding investors are Fountain Healthcare Partners (Dublin, Ireland), funds
managed by Tekla Capital Management, LLC (Boston, Massachusetts), HealthCap(Stockholm, Sweden) and EarlyBird Venture Capital (Berlin, Germany).

About KYORIN Pharmaceutical Co., Ltd.
Foundation:
December 1923
President & CEO:
Shigeru Ogihara
Annual Sales:
JPY 96.336 billion (Fiscal Year ending on March 31, 2020)
Employees:
1,502 (as of March 31, 2020)
Overview:
Trusted among patients and professionals in the medical industry, KYORIN
Pharmaceutical strives to be a company that contributes to the public health and isrecognized as a one with social significance by improving its presence in thespecific therapeutic areas and through global discovery of novel drugs. KYORINPharmaceutical uses franchise customer strategy where its marketing efforts arefocused on respiratory medicine, otolaryngology and urology. In drug discovery,
it is deploying 'selection and concentration' and promoting activities aimed at
first-in-class drug discovery, such as actively searching for and introducing
external drug discovery themes as well as multi-tiered program development.